Tag - AIM

Developments

AIM highlights compelling data for Ampligen in PC at conference in Poland

AIM ImmunoTech (NYSE American: AIM) announced the latest in a growing body of positive data from its lead clinical program, Ampligen, for the treatment of pancreatic cancer (PC), in a presentation at the 5th Annual...

September 5, 2025

Developments

First patient dosed in Aim’s Phase 2 study of Ampligen and Imfinzi in pancreatic cancer

AIM ImmunoTech (NYSE American:AIM) announced that the first new patient has been dosed in the Phase 2 study of its Ampligen and Astra Zeneca’s anti-PD-L1 immune checkpoint inhibitor, Imfinzi, as a potential combination...

February 25, 2025

Developments

AIM addresses avian flu with follow-up clinical study of Ampligen and FluMist combo

AIM ImmunoTech (NYSE:AIM) has announced plans for a follow-up clinical study to evaluate the potential avian influenza combination therapy of its Ampligen with Astra Zeneca’s (NASDAQ: AZN) FluMist. According to AIM, the...

February 7, 2025

Markets

Maxim ups AIM ImmunoTech PT to $5 from $2

Maxim Group raised its price target for AIM ImmunoTech (NYSE American:AIM) to $5 from $2, citing a strengthened balance sheet and a $14.54-million award from the NCI to study its Ampligen drug candidate in up to five...

April 6, 2020

Tag - AIM

AIM highlights compelling data for Ampligen in PC at conference in Poland

First patient dosed in Aim’s Phase 2 study of Ampligen and Imfinzi in pancreatic cancer

AIM addresses avian flu with follow-up clinical study of Ampligen and FluMist combo

Maxim ups AIM ImmunoTech PT to $5 from $2

Subscribe